ArticleCancers2026

Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy.

Cirino Botta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.